Role of platelet-rich plasma combined with antibiotics in inhibition of escherichia coli
-
摘要: 目的 探究富血小板血浆(platelet-rich plasma，PRP)及其与抗生素头孢呋辛钠联合应用在体外对大肠埃希菌的作用。方法 从六安市中心血站获取健康志愿者捐献的血小板作为PRP来源。将一定浓度的大肠埃希菌质控菌株与PRP及抗生素头孢呋辛钠共同培养，观察PRP单独应用及与抗生素头孢呋辛钠联合应用时的抑菌情况。结果 2 mg/L头孢呋辛钠在12 h内无抑菌作用，4 mg/L头孢呋辛钠可在24 h内发挥抑菌作用，8 mg/L头孢呋辛钠可在48 h内发挥较强抑菌作用。PRP单独应用可以在24 h内发挥抑菌作用，与2 mg/L头孢呋辛钠联合应用在12 h内可抑制大肠埃希菌生长，与4 mg/L头孢呋辛钠联合应用在24 h内可抑制大肠埃希菌生长，与8 mg/L头孢呋辛钠联合应用在36 h内可抑制大肠埃希菌生长。结论 PRP单独应用在体外可抑制大肠埃希菌的生长，与抗生素联合应用可发挥抑菌作用，并减轻抗生素的使用剂量。Abstract: Objective To investigate the effect of platelet-rich plasma(PRP) and its combination with cefuroxime sodium on Escherichia coli in vitro.Methods Apheresis platelets donated by healthy volunteers were obtained from the Blood station of Lu'an Blood Center as the source of PRP. In order to explore the antibacterial effect of PRP alone or in combination with cefuroxime sodium, a certain concentration of Escherichia coli quality control strains were co-cultured with PRP and cefuroxime sodium.Results 2 mg/L cefuroxime sodium had no antibacterial effect within 12 hours, 4 mg/L cefuroxime sodium had antibacterial effect within 24 hours, and 8 mg/L cefuroxime sodium had strong antibacterial effect within 48 hours. The application of PRP alone could exert antibacterial effect within 24 hours, the combination with 2 mg/L cefuroxime sodium could inhibit the growth of Escherichia coli within 12 hours, the combination with 4 mg/L cefuroxime sodium could inhibit the growth of Escherichia coli within 24 hours, and the combination with 8 mg/L cefuroxime sodium could inhibit the growth of Escherichia coli within 36 hours.Conclusion Platelet-rich plasma alone could inhibit the growth of Escherichia coli in vitro, and combined with antibiotics could exert bacteriostatic effect and reduce the dosage of antibiotics.
-
Key words:
- platelet-rich plasma /
- escherichia coli /
- cefuroxime sodium
-
-
[1] Lin MY, Lin CS, Hu S, et al. Progress in the Use of Platelet-rich Plasma in Aesthetic and Medical Dermatology[J]. J Clin Aesthet Dermatol, 2020, 13(8): 28-35.
[2] Wu PI, Diaz R, Borg-Stein J. Platelet-Rich Plasma[J]. Phys Med Rehabil Clin N Am, 2016, 27(4): 825-853. doi: 10.1016/j.pmr.2016.06.002
[3] 江琰笛, 张勇, 陶崑, 等. 慢性感染性创面分离的多重耐药菌分布研究[J]. 中国消毒学杂志, 2020, 37(8): 570-572. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXD202008004.htm
[4] 王灿灿. 创面感染病原微生物种类及分布对临床抗生素应用的影响[J]. 实用医技杂志, 2022, 29(6): 646-650. doi: 10.19522/j.cnki.1671-5098.2022.06.027
[5] 吴日钊, 霍景山, 刘海燕, 等. 富血小板血浆对MRSA的体外抑菌作用研究[J]. 中国医药科学, 2020, 10(9): 198-202. doi: 10.3969/j.issn.2095-0616.2020.09.059
[6] Chen L, Wang C, Liu H, et al. Antibacterial effect of autologous platelet-rich gel derived from subjects with diabetic dermal ulcers in vitro[J]. J Diabetes Res, 2013, 2013: 269527.
[7] Hasiba-Pappas SK, Tuca AC, Luze H, et al. Platelet-Rich Plasma in Plastic Surgery: A Systematic Review[J]. Transfus Med Hemother, 2022, 49(3): 129-142. doi: 10.1159/000524353
[8] Smith OJ, Wicaksana A, Davidson D, et al. An evaluation of the bacteriostatic effect of platelet-rich plasma[J]. Int Wound J, 2021, 18(4): 448-456. doi: 10.1111/iwj.13545
[9] 任少强, 杨静, 闫萍, 等. 177例慢性难愈性创面病原体感染现状及耐药性的回顾分析[J]. 中华医院感染学杂志, 2019, 29(15): 2348-2352. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201915026.htm
[10] 孙永宁, 石莉娜, 张丹晨, 等. 骨科创面感染产超广谱β-内酰胺酶大肠埃希菌的耐药性及产酶因素分析[J]. 中华医院感染学杂志, 2018, 28(11): 1670-1673. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201811017.htm
[11] Tang R, Wang S, Yang J, et al. Application of platelet-rich plasma in traumatic bone infections[J]. Expert Rev Anti Infect Ther, 2021, 19(7): 867-875. doi: 10.1080/14787210.2021.1858801
[12] 高强, 唐晶. 肛周脓肿病原菌分布及对抗菌药物的耐药性分析[J]. 中国医学创新, 2022, 19(13): 161-165. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYCX202213039.htm
[13] 宋思惠, 秦建平. 肛周脓肿的诊治进展[J]. 中国医药导报, 2019, 16(32): 47-50. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201932012.htm
[14] 柴瑞琪, 樊志敏. 345例首发肛周脓肿患者脓液中病原菌分布及耐药性分析[J]. 临床医药文献电子杂志, 2018, 5(28): 45-46. https://www.cnki.com.cn/Article/CJFDTOTAL-LCWX201828024.htm
[15] 俞善春. 293株大肠埃希菌临床分布及耐药性分析[J]. 安徽医专学报, 2022, 21(1): 92-94. https://www.cnki.com.cn/Article/CJFDTOTAL-AHWZ202201033.htm
[16] 菅记涌, 解泽强, 全秀秀, 等. 大肠埃希菌临床分布和耐药性变化[J]. 临床血液学杂志, 2017, 30(4): 263-266. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ201704005.htm
[17] Attili AR, Iacoucci C, Serri E, et al. Antibacterial Properties of Canine Platelet-Rich Plasma and Other Non-Transfusional Hemo-Components: An in vitro Study[J]. Front Vet Sci, 2021, 8: 746809.
[18] Maghsoudi O, Ranjbar R, Mirjalili SH, et al. Inhibitory Activities of Platelet-Rich and Platelet-Poor Plasma on the Growth of Pathogenic Bacteria[J]. Iran J Pathol, 2017, 12(1): 79-87.
[19] de la Portilla F, Jiménez-Salido A, Araujo-Miguez A, et al. Autologous Platelet-Rich Plasma in the Treatment of Perianal Fistula in Crohn's Disease[J]. J Gastrointest Surg, 2020, 24(12): 2814-2821.
[20] Göttgens KW, Smeets RR, Stassen LP, et al. Treatment of Crohn's disease-related high perianal fistulas combining the mucosa advancement flap with platelet-rich plasma: a pilot study[J]. Tech Coloproctol, 2015, 19(8): 455-459.
[21] Çetinkaya RA, Yenilmez E, Petrone P, et al. Platelet-rich plasma as an additional therapeutic option for infected wounds with multi-drug resistant bacteria: in vitro antibacterial activity study[J]. Eur J Trauma Emerg Surg, 2019, 45(3): 555-565.
[22] 费军, 薛超. 富血小板血浆负载抗生素联合Masquelet技术治疗感染性骨缺损的相关问题[J]. 中华创伤杂志, 2021, 37(4): 295-300.
[23] 赵东军, 王晗, 杨森, 等. 抗生素骨水泥填充技术联合自体富血小板血浆对慢性创面修复效果及病人生活质量的影响[J]. 安徽医药, 2022, 26(8): 1558-1561. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYY202208017.htm
[24] Zhang W, Guo Y, Kuss M, et al. Platelet-Rich Plasma for the Treatment of Tissue Infection: Preparation and Clinical Evaluation[J]. Tissue Eng Part B Rev, 2019, 25(3): 225-236.
[25] Li FX, Li Y, Qiao CW, et al. Topical use of platelet-rich plasma can improve the clinical outcomes after total knee arthroplasty: A systematic review and meta-analysis of 1316 patients[J]. Int J Surg, 2017, 38: 109-116.
-
下载:
图(2)
计量
- 文章访问数: 1600
- PDF下载数: 575
- 施引文献: 0